<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204729">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000241</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-07200-1</org_study_id>
    <secondary_id>R01-07200-1</secondary_id>
    <nct_id>NCT00000241</nct_id>
  </id_info>
  <brief_title>Flupenthixol Decanoate in Methamphetamine Smoking - 1</brief_title>
  <official_title>Flupenthixol Decanoate in Methamphetamine Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Friends Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate
      for treatment of methamphetamine dependence. Also, study will compare flupenthixol with
      desipramine in blocking methamphetamine self-administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1994</start_date>
  <completion_date>May 1996</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Methamphetamine use</measure>
  </primary_outcome>
  <enrollment>58</enrollment>
  <condition>Substance-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flupenthixol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Please contact site for information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Gawin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1994</verification_date>
  <lastchanged_date>June 23, 2005</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Flupenthixol</mesh_term>
    <mesh_term>Flupenthixol decanoate</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
